CAMBRIDGE, Mass., March 20, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- Infinity Pharmaceuticals (Nasdaq:INFI) announced today that its Board of Directors unanimously voted to approve a corporate governance initiative to declassify the Board. In addition, the Board determined that Eric S. Lander, Ph.D. and Franklin Moss, Ph.D. now qualify as “independent directors” under the NASDAQ Marketplace Rules, increasing the percentage of the company’s independent directors from 67% to 83%.
